Inhaltsverzeichnis

List of Abbreviations 15

I. INTRODUCTION 21
   A. Overview 21
   B. Outline of the dissertation 25
   C. Scope of the dissertation 25

II. PHARMACEUTICAL INVENTIONS, INNOVATIONS & PRODUCTS 28
   A. Cumulative nature of inventions 28
      1. Basic and second generation inventions 29
         a) Improvement inventions 30
         b) Selection inventions 30
   B. Inventions and innovations in pharmaceutical field 32
      1. Inventions and patents in pharmaceutical field 32
         a) Product invention and the absolute character of its protection 33
         b) Hierarchy of pharmaceutical patents 34
      2. Innovations in pharmaceutical field 36
         a) Invention v. innovation 36
         b) NMEs as the core of pharmaceutical innovation 37
   C. Second generation inventions and patents in pharmaceuticals 38
      1. Product inventions and patents 39
         a) Species selection inventions 39
         b) Optical isomers 43
         c) Crystalline forms 46
         d) Metabolites and prodrugs 47
         e) Esters and salts 49
         f) Dosage forms 49
         g) Combinations of active ingredients 50
Inhaltsverzeichnis

2. Use inventions 50
a) New Use/New method of treatment 50
b) Dosage regime 52
3. Process inventions 52
a) Process 52
b) Intermediates 53
D. Pharmaceutical products in the market 53
1. New medical entities, new molecular entities 54
2. Similar or equivalent "me-too" products 54
3. Second generation products 56
4. Generic drugs 57
E. Summary 58

III. SPECIFICITIES IN PHARMACEUTICALS AND RECENT DEVELOPMENTS 59
A. Innovating and inventing in pharmaceutical industry 59
1. Specificities in the drug development process 59
   a) Highly regulated industry 59
   b) R&D – a costly and lengthy road to a medicine 60
   c) Uncertainties in post-invention development 64
       (1) Scientific uncertainty: Unpredictability of substances 64
       (2) Regulatory and market uncertainties 65
d) Information rich chemicals 66
2. Specificities in the market for pharmaceuticals 67
   a) Imitation with negligible cost and much reduced risk 67
   b) Prescription based purchase: A disconnection between choosers and payers 68
c) Information asymmetry and high loyalty to a medicine 69
d) Pricing 70
3. Specificities of the patent protection for pharmaceuticals 72
   a) Patent protection for industrial technologies 72
   b) Patent protection in the pharmaceutical industry 74
B. Challenges and overcoming efforts 76
   1. Decreased R&D productivity 78
   2. Dearth of new medical entities 80
      a) Significance of NMEs 80
      b) Decreased number of NMEs 80
c) Potential reasons for the decrease 83
   (1) Decrease in solvable scientific problems 83
   (2) Stringent safety regulations 84
   (3) Problem of over-disclosure 84
   (4) Early and numerous abandonments of potential candidates 85
3. Patent cliffs of blockbuster medications 86
4. Frequent merger and acquisitions (M&As) and in-licensing 86
5. Drastic increase of second generation inventions 88
   a) Life cycle management or evergreening 89
   b) Drastic increase of this activity supported by the number of second generation patents 91
C. Summary 93

IV. STANDARDS OF PATENTABILITY FOR PHARMACEUTICAL SELECTION INVENTIONS 95
A. Novelty and anticipation 96
   1. Introduction 96
   2. Examination of novelty 98
   3. Inherent anticipation and enablement 103
   4. Novelty of selection inventions 106
      a) Species selection inventions 106
      b) Optical isomers 117
      c) Crystalline forms 127
      d) Metabolite 130
   5. Analysis and conclusion 133
B. Inventive step / Non-obviousness 134
   1. Inventive step in patentability requirements 135
   2. Examination of inventive step 136
   3. Inventive step requirement for selection inventions 144
      a) Species selection invention 144
      b) Optical isomers 150
      c) Crystalline forms 157
      d) Metabolites 164
   4. Analysis and conclusion 164
C. Disclosure requirement 167
   1. Written description requirement 168
2. Enablement requirement 171
   a) Enablement requirement 171
   b) Enablement requirements in the patent law 175
      (1) Enablement as a requirement for anticipation 175
      (2) Basic similarity of the two enablement requirements 176
      (3) Differences between the two enablement requirements 177
3. Disclosure requirement of selection inventions 178
   a) Species selection invention 178
   b) Optical isomers 179
   c) Crystalline forms 180
D. Conclusion 180

V. IMPLICATIONS OF THE PATENTABILITY REQUIREMENTS ON INNOVATION AND COMPETITION IN THE PHARMACEUTICAL INDUSTRY 184
A. Concerns about lowered patentability 185
   1. General concerns about lowered patentability 185
      a) Superfluous second generation patents 185
      b) Increased patent exclusivities and amplified uncertainties thereof 187
      c) Encouraged waste of resources 190
      d) Hindrance of pharmaceutical innovation 192
   2. Concerns about the novelty requirements 194
      a) Language dependent prior art disclosure problem 194
      b) Rendering inventive step requirement meaningless 196
      c) Potential concerns of "direct and unambiguous" disclosure requirement 198
B. Implications considering the breadth of selection patents 198
   1. Scope of the protection 199
   2. Scope of selection patents 203
      a) Species selection patents 203
      b) Optical isomers 203
      c) Metabolite 206
      d) Polymorphs 208
   3. Analysis and conclusion 209
C. Implications considering the length of selection patents 210
   1. Patent term and patent term extension 211
      a) In Europe 212
      b) In the United States 213
      c) In Korea 214
   2. Patent term extension on selection patents 215
      a) Species selection patents 215
      b) Optical isomers 215
      c) Polymorphs 218
      d) Metabolite 218
   3. Analysis and conclusion 218

D. Implications on the competition in the pharmaceutical industry 222
   1. Introduction 222
   2. Quasi-obstacles of generics market entry 225
      a) Scope of second generation patents 225
      b) Length of second generation patents 227
      c) Delayed filing of second generation patent applications 227
   3. Real obstacles to generics’ market entry 229
      a) Automatic thirty-month stay and new list up in the Orange Book in the United States 229
      b) Pendency of patent applications: Uncertainty 231
         (1) Pendency of patent applications 231
         (2) Filing of divisional applications 232
      c) Active movement of the market to new products 237
      d) Along with very specific patents on the secondary products 240
   4. Analysis and conclusion 242

E. Summary and conclusion 243

VI. PROPOSALS 245
A. Introduction 247
B. Nature of selection inventions 249
   1. Different natures of selection inventions 249
      a) Species selection invention 249
      b) Other selection inventions 251
   2. Selection inventions from the era of penicillin to the 21th century 251
      a) Early medications and the novelty requirement 251
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>b) “Made available to the public” for the first time</td>
<td>252</td>
</tr>
<tr>
<td>3. Analysis and conclusion</td>
<td>254</td>
</tr>
<tr>
<td>C. Proposals on the breadth of patents</td>
<td>255</td>
</tr>
<tr>
<td>1. Arguments on the breadth of patents</td>
<td>255</td>
</tr>
<tr>
<td>a) Arguments for a broader patent scope</td>
<td>256</td>
</tr>
<tr>
<td>b) Arguments against a broader patent scope</td>
<td>258</td>
</tr>
<tr>
<td>c) Arguments on patent scope with consideration of other relevant factors</td>
<td>260</td>
</tr>
<tr>
<td>2. Interim conclusion</td>
<td>261</td>
</tr>
<tr>
<td>3. Solutions to the overlapping scope with species selection invention</td>
<td>264</td>
</tr>
<tr>
<td>a) Voluntary licensing agreements</td>
<td>265</td>
</tr>
<tr>
<td>b) Non-voluntary licenses</td>
<td>266</td>
</tr>
<tr>
<td>(1) Compulsory licenses</td>
<td>267</td>
</tr>
<tr>
<td>(2) Case law relevant to compulsory licenses</td>
<td>269</td>
</tr>
<tr>
<td>c) Reverse doctrine of equivalents</td>
<td>272</td>
</tr>
<tr>
<td>d) Conclusion</td>
<td>274</td>
</tr>
<tr>
<td>D. Proposals on the length of patents</td>
<td>275</td>
</tr>
<tr>
<td>1. Arguments on the length of patents</td>
<td>275</td>
</tr>
<tr>
<td>2. Proposals on the length of patents</td>
<td>277</td>
</tr>
<tr>
<td>a) Proposal on the length of basic patents</td>
<td>277</td>
</tr>
<tr>
<td>(1) Introduction</td>
<td>277</td>
</tr>
<tr>
<td>(2) Proposed term of basic patents</td>
<td>278</td>
</tr>
<tr>
<td>(3) The basis of the proposal</td>
<td>279</td>
</tr>
<tr>
<td>(4) Expected effects</td>
<td>281</td>
</tr>
<tr>
<td>b) Proposal on the patent term extension of second generation patents</td>
<td>282</td>
</tr>
<tr>
<td>E. Proposals on the patentability requirements</td>
<td>283</td>
</tr>
<tr>
<td>1. Introduction: Technology specific patentability standards</td>
<td>283</td>
</tr>
<tr>
<td>2. Proposals on the novelty requirement</td>
<td>286</td>
</tr>
<tr>
<td>a) Arguments on the novelty requirement</td>
<td>286</td>
</tr>
<tr>
<td>b) Proposal on the novelty requirement of species selection invention</td>
<td>287</td>
</tr>
<tr>
<td>(1) Meaning of something “made available to the public” in the pharmaceutical industry</td>
<td>287</td>
</tr>
<tr>
<td>(2) A patent as a double-edged sword to NMEs</td>
<td>289</td>
</tr>
</tbody>
</table>
(3) Statutory exceptions to the novelty requirement and considerations thereof 290
(4) Proposed novelty requirement for NMEs 291
(5) Appreciation of the Olanzapine decision and its expected results 293
c) Discussion on the novelty requirement of other selection inventions 294

3. Proposals on the inventive step requirement 294
a) Arguments on the inventive step requirement 295
   (1) Arguments for a strict inventive step requirement 295
   (2) Arguments for a strict inventive step requirement together with broader protection 296
   (3) Arguments against a strict inventive step requirement 297
   (4) Arguments for the relaxed inventive step requirement in risky and expensive R&D fields 297
b) Proposal on the inventive step of species selection inventions 299
c) Proposal on the inventive step of other selection inventions 300
   (1) Introduction 300
   (2) Proposed standard to assess the inventive step 301
   (3) Basis of the proposal 301
   (4) Expected effects 304

4. Discussions on the sufficiency requirement 306
a) Discrepancy between the scope of and the disclosure of a genus claim 306
b) Stringent disclosure requirement of the basic invention 307
c) Conclusion 309

F. Conclusion 309

VII. FINAL CONCLUSIONS 312

List of Statutory Instruments 321

List of Case Laws 323

Bibliography 333